BUTORPHANOL TARTRATE

Post-LOE

butorphanol tartrate

Pfizer

ANDANASALSPRAY, METERED

Approved

Aug 2001

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

BUTORPHANOL TARTRATE (butorphanol tartrate) by Pfizer is mechanism of action butorphanol is a partial opioid agonist at the mu opioid receptor and a full agonist at the kappa opioid receptor. Approved for pain severe enough to require an opioid analgesic, for which alternative treatments are inadequate. First approved in 2001.

Drug data last refreshed 20h ago

Mechanism of Action

Mechanism of Action Butorphanol is a partial opioid agonist at the mu opioid receptor and a full agonist at the kappa opioid receptor. The principal therapeutic action of butorphanol is analgesia. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions,…

Indications (2)

pain severe enough to require an opioid analgesic for which alternative treatments are inadequate

Worked on BUTORPHANOL TARTRATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.